Sawai Group Holdings Co., Ltd. · TSE:4887
Sawai — Investor Day (October 2026)
21 slides from Sawai's investor day presentation, Oct 2, 2026
Slide 1: IR Day 2026
Sawai Group Holdings Co., Ltd. IR Day 2026 October 2, 2026
Slide 2: IR Day 2026 Speakers
IR Day 2026 Speakers Sawai Group Holdings Representative Director, Chairman and President Mitsuo Sawai Director, Senior Managing Executive Officer Toshiomi Nakate Director, Senior Executive Officer Taku Nakaoka Outside Director Masatoshi Ohara Outside Director Masayuki Mitsuka Outside Director Yasuk
Slide 3: IR Day 2026 Today's Schedule
IR Day 2026 Today’s Schedule Contents Speakers 14：05～14：25 Director, Senior Managing Executive 1. Initiatives to Establish a Stable Supply Officer System Toshiomi Nakate 14：25～14：45 Outside Director 2. Selection Process and Nomination Masatoshi Ohara Discussions for Senior Management 14：45～15：30 3.
Slide 4: Initiatives to Establish a Stable Supply System
01. Initiatives to Establish a Stable Supply System October 2, 2026 Director, Senior Managing Executive Officer Representative Director and President of Sawai Pharmaceutical Co., Ltd. Toshiomi Nakate
Slide 5: Trends in Our Company's Business Growth
Trends in Our Company's Business Growth Launch Increase in New Production Products Volume Revenue Production Volume （Unit: 100 Million Yen) （Unit: 100 Million Tablets) 2,500 Withdrawal from U.S. 30,000 Revenue Production Volume Expansion into the U.S. 25,000 2,000 20,000 1,500 16,637 16,622 16,568 1
Slide 6: Number of New Products Listed
Number of New Products Listed ▌Number of Ingredients Listed 35 30 25 20 15 10 5 0 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Number of new ingredients listed in NHI for the generic drug industry as a whole Number of new Ingredients from our company listed in NHI ▌Products Listed in 2026 Nine
Slide 7: Value-added Product Development
Value-added Product Development Ingenuity for Patients Easy-to-swallow From capsules to tablets Reduction in tablet size Taste improvement formulations Developing orally Replacing large, hard-to- Reducing the size of large, Applying coatings and other disintegrating tablets, jellies, swallow capsule
Slide 8: Formulation Technology (SAWAI HARMOTECH)
Formulation Technology （ SAWAI HARMOTECH ® ） ▌Technology Categories Core Particle Orally Disintegrating Tablet Manufacturing Technology Manufacturing Technology Printing Technology Formulation Evaluation Film Coating Technology Technology 7 © 2026 SAWAI GROUP HOLDINGS Co., Ltd.
Slide 9: Production System
Production System Group-wide Production Capacity* ▍Kyushu Factory ▍Sanda Factory 20.5 Billion Tablets ( S a n d a C i t y, H yo g o P r e f e c t u r e ) ( I i z u k a C i t y, F u k u o k a P r e f e c t u r e ) *Theoretical capacity based on equipment Site Area： 14,686㎡ Site Area： 70,351㎡ Producti
Slide 10: In-house Production Capacity and Number of New Graduates Hired
In-house Production Capacity and Number of New Graduates Hired Operation will start at Daini Kyushu Factory: Step 2 Operation will start Seima Daini Factory Operation started at Daini Kyushu Operation will start Seima Daisan Factory Number of New Graduates Hired （Unit： Persons） Factory: Step 1（July
Slide 11: Initiatives to Improve Productivity
Initiatives to Improve Productivity Scale Optimization Improving efficiency by expanding manufacturing lot sizes. Reducing per-unit manufacturing labor hours and setup frequency through scale-ups. Continuous Product Enhancement Improvement of Manufacturing Methods Improving efficiency by simplifying
Slide 12: Initiatives to Strengthen Quality Assurance (Enhancing Collaboration between HQ and Factory)
Initiatives to Strengthen Quality Assurance (Enhancing Collaboration between HQ and Factory) Company-wide Collaboration Two-way Manufacturing and Manufacturing (Factory) Platform Collaboratio Sales Business(HQ) Autonomous control n on-site Tripartite Governance Implementation of ICH Q10 Management r
Slide 13: Initiatives to Strengthen Quality Assurance (Management Review, ICH Q10)
Initiatives to Strengthen Quality Assurance (Management Review, ICH Q10 Pharmaceutical Quality) Operating strict, regulatory-compliant Pharmaceutical Quality System(PQS) and establishing stable supply system through management commitment • Hierarchical management review utilizing bottom-up and top-d
Slide 14: Reliable Technology Transfer of New Products to Factories
Reliable Technology Transfer of New Products to Factories Implement reliable technology transfer through seamless coordination between transfer phases and management reviews Management Review Report and share evaluation data Directives / Feedback Technology Transfer Process Phase 1: R&D / Preparatio
Slide 15: Fostering Quality Culture
Fostering Quality Culture Consolidate input from all participating members to articulate and 1st Step (Defining Ideal State) share vision of Production Division's "ideal state" Conduct regular surveys to quantitativel y visualize the gap betw een 2nd Step (Gap Anal ysis) the ideal state and current
Slide 16: Sustainable Enhancement of Corporate Value
Growth Strategies and Competitive Advantages Enhancing corporate value by establishing competitive advantages through the trinity of R&D, Production, and Quality Our Share １６％ New Product Development Capabilities & Portfolio Optimization 190 other Company A companies Continuous development of value-
Slide 17: Selection Process and Nomination Discussions for Senior Management
02. Selection Process and Nomination Discussions for Senior Management October 2, 2026 Outside Director Masatoshi Ohara
Slide 18: Nomination, Remuneration and Other Governance Committee
Nomination, Remuneration and Other Governance Committee ▌Functions of the Committee Appointment and dismissal of Succession planning and development Deliberation on remuneration for senior 1 senior management 2 3 management and corporate officers plans for future management candidates 17 © 2026 SAWA
Slide 19: Overview: Top Management Selection Process
Overview：Top Management Selection Process R o a d ma p F o rmu la tio n S e le c tio n o f Imp le me n ta ti D e ve lo p me n t o f E va lu a tio n S e n io r on of C rite ria & M a n a g e me n t D e ve lo p me n t D e ve lo p me n t C a n d id a te s P la n s P la n s R e p la c e me n t C a n d i
Slide 20: Selection Criteria for Senior Management
Selection Criteria for Senior Management ▌Senior Management Skills Corporate Healthcare Global Business Medicine and Management Pharmaceuticals Finance, Accounting Legal and Risk Sustainability and and Taxation Management ESG ▌Ideal Executive Profile (Excerpt) Sawai Pharmaceutical Corporate Philosop
Slide 21: Disclaimer
Disclaimer Forward–looking statements contained in this document are based on several assumptions and do not guarantee or assure the achievement of projected figures and the implementation of initiatives. Contact Sawai Group Holdings Co., Ltd. IR Group, Group Finance Department E-Mail ir@sawai.co.jp